Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 11/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28103549 | 0.87 | ADRA2A (0.69) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL2776944 | 0.86 | TAAR1 (0.68) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL12716493 | 0.85 | TAAR1 (0.66) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL11289078 | 0.84 | TAAR1 (0.56) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL23107884 | 0.80 | TAAR1 (0.51) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL953782 | 0.80 | TAAR1 (1.00) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL11291001 | 0.79 | TAAR1 (0.54) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL954941 | 0.79 | TAAR1 (0.54) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL955142 | 0.79 | TAAR1 (0.82) | TAAR1ADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL6112047 | 0.79 | ADRA2A (0.59) | TAAR1ADRA2AADRA2BADRA2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114072444-B | Curable composition, cured product, overcoat film, flexible wiring board, and method for producing same | 日保丽公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-2206496-B1 | SCREENING OF INHIBITORS OF FORMATION OF PYROGLUTAMIC ACID IN AMYLOID BETA PEPTIDE | PROBIODRUG AG (DE) | 2014-09-17 | — | — | EP | disclosed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | disclosed |
| EP-1961416-B1 | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. | PROBIODRUG AG (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2289498-A1 | Use of inhibitors of glutaminyl clyclase | Probiodrug AG (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | disclosed |
| EP-2206496-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2010-07-14 | — | — | EP | disclosed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | disclosed |
| EP-1675578-A2 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| EP-1620082-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005039548-A2 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | PROBIODRUG AG (DE) | 2005-03-17 | — | — | US | disclosed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098625-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| EP-0064820-A1 | Substituted imidazole and imidazoline derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1982-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | GLS, QPCT, GLS2 | TAAR1 4856/4885ADRA2A 3998/4885ADRA2B 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.